Deniz Kirac1, Aysun Erdem Yaman2, Tansu Doran3, Mujgan Mihmanli4, Elif Cigdem Keles5. 1. Department of Medical Biology, Faculty of Medicine, Yeditepe University, Istanbul, Turkey. denizyat@hotmail.com. 2. Department of Cardiology, Istanbul Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey. 3. Department of Medical Biology, Faculty of Medicine, Yeditepe University, Istanbul, Turkey. 4. Department of Biochemistry, Istanbul Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey. 5. Department of Biostatistics and Medical Informatics, Faculty of Medicine, Yeditepe University, Istanbul, Turkey.
Abstract
BACKGROUND: In some stent implanted patients, cardiovascular events (CE) may occur. Acetylsalicylic acid (ASA) is routinely administered to these patients in order to prevent the occurrence of CE. CE may be related to gene variations which cause ASA resistance (AR). Therefore, it was aimed to investigate the relationship between COX-1, COX-2, CYP2C9 and CYP2C19 variations with CE due to AR. MATERIALS AND RESULTS: Seventy-four stent implanted patients, using 100 mg of ASA per day during five years were enrolled into the study. Following stent implantation, thirty-eight patients who had a CE within five years due to AR and 36 patients without CE were enrolled in patient and control group, respectively. AR was confirmed by platelet aggregation testing. After DNA isolation from blood; COX-1, COX-2, CYP2C19 and CYP2C9 variations were investigated with real-time polymerase chain reaction. At the end of this study, heterozygous genotype of COX-1 was found statistically high in patients whereas heterozygous genotype of CYP2C19*17 was found statistically high in controls. The presence of C and G allele in COX-1 and COX-2 were found statistically high in patients, respectively. The presence of T allele in CYP2C19*17 was found statistically high in controls. Heterozygous genotype of COX-1 variation was found statistically high in patients who have AR. Additionally heterozygous genotype of CYP2C19*17 was found statistically high in patients who have low thrombosis risk. CONCLUSIONS: COX-1 and COX-2 gene mutations may increase the risk of CE due to AR whereas CYP2C19*17 may have a protective effect in this process.
BACKGROUND: In some stent implanted patients, cardiovascular events (CE) may occur. Acetylsalicylic acid (ASA) is routinely administered to these patients in order to prevent the occurrence of CE. CE may be related to gene variations which cause ASA resistance (AR). Therefore, it was aimed to investigate the relationship between COX-1, COX-2, CYP2C9 and CYP2C19 variations with CE due to AR. MATERIALS AND RESULTS: Seventy-four stent implanted patients, using 100 mg of ASA per day during five years were enrolled into the study. Following stent implantation, thirty-eight patients who had a CE within five years due to AR and 36 patients without CE were enrolled in patient and control group, respectively. AR was confirmed by platelet aggregation testing. After DNA isolation from blood; COX-1, COX-2, CYP2C19 and CYP2C9 variations were investigated with real-time polymerase chain reaction. At the end of this study, heterozygous genotype of COX-1 was found statistically high in patients whereas heterozygous genotype of CYP2C19*17 was found statistically high in controls. The presence of C and G allele in COX-1 and COX-2 were found statistically high in patients, respectively. The presence of T allele in CYP2C19*17 was found statistically high in controls. Heterozygous genotype of COX-1 variation was found statistically high in patients who have AR. Additionally heterozygous genotype of CYP2C19*17 was found statistically high in patients who have low thrombosis risk. CONCLUSIONS: COX-1 and COX-2 gene mutations may increase the risk of CE due to AR whereas CYP2C19*17 may have a protective effect in this process.
Authors: J P Lewis; S H Stephens; R B Horenstein; J R O'Connell; K Ryan; C J Peer; W D Figg; S D Spencer; M A Pacanowski; B D Mitchell; A R Shuldiner Journal: J Thromb Haemost Date: 2013-09 Impact factor: 5.824
Authors: Mariana R Botton; Xingwu Lu; Geping Zhao; Elena Repnikova; Yoshinori Seki; Andrea Gaedigk; Eric E Schadt; Lisa Edelmann; Stuart A Scott Journal: Hum Mutat Date: 2019-11 Impact factor: 4.878
Authors: D Kirac; A Erdem; T Avcilar; K Yesilcimen; A I Guney; A Emre; S Yazici; S Terzi; E C Kaspar; S E Cetin; T Isbir Journal: Cell Mol Biol (Noisy-le-grand) Date: 2016-01-19 Impact factor: 1.770
Authors: Argentina Ornelas; Niki Zacharias-Millward; David G Menter; Jennifer S Davis; Lenard Lichtenberger; David Hawke; Ernest Hawk; Eduardo Vilar; Pratip Bhattacharya; Steven Millward Journal: Cancer Metastasis Rev Date: 2017-06 Impact factor: 9.264
Authors: Tomasz P Stys; Maheedhar Gedela; Smitha N Gowda; Valerie Bares; Lauren Fanta; Marian Petrasko; Catherine Hajek; Eric Larson; Adam T Stys Journal: Indian Heart J Date: 2021-03-17